In the latest trading session, 0.74 million Cardiff Oncology Inc (NASDAQ:CRDF) shares changed hands as the company’s beta touched 1.96. With the company’s most recent per share price at $3.24 changed hands at -$0.28 or -7.81% at last look, the market valuation stands at $145.12M. CRDF’s current price is a discount, trading about -98.15% off its 52-week high of $6.42. The share price had its 52-week low at $0.94, which suggests the last value was 70.99% up since then. When we look at Cardiff Oncology Inc’s average trading volume, we note the 3-month average coming to 1.92 million.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Instantly CRDF was in red as seen in intraday trades today. With action -27.24%, the performance over the past five days has been red. The drop to weekly highs of 4.54 subtracted -7.81% to the stock’s daily price. The company’s shares are showing year-to-date upside of 119.26%, with the 5-day performance at -27.24% in the red. However, in the 30-day time frame, Cardiff Oncology Inc (NASDAQ:CRDF) is -44.43% down.
Cardiff Oncology Inc (CRDF) estimates and forecasts
Data shows that the Cardiff Oncology Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 184.65% over the past 6 months, a -5.38% in annual growth rate that is considerably lower than the industry average of 13.00%. Year-over-year growth is forecast to reach -18.00% down from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 70k. 4 analysts are of the opinion that Cardiff Oncology Inc’s revenue for the current quarter will be 70k. The company’s revenue for the corresponding quarters a year ago was 108k and 141k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -35.20%. The estimates for the next quarter sales put growth at -50.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 35.42%. The 2024 estimates are for Cardiff Oncology Inc earnings to decrease by -5.11%.
